UNSPSC 51391731: Norfenefrine

This classification denotes an alpha-adrenergic agonist with the molecular formula C8H11NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D2P3M6SRN5, chemically known as r,s-norphenylephrine but generally known as norfenefrine, which bears US NIH Compound Identifier 4538. European Medicines Agency schedules Norfenefrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09364MIG.

UNSPSC 51391731 Norfenefrine is a Commodity code that in recent state and local procurement covers the purchase of pharmaceutical products and related medical supplies for public health initiatives, though the recent opportunities posted under it diverge from the code's nominal pharmaceutical scope. Seminole County, Florida solicited naloxone and drug deactivation systems through an IFB (Invitation for Bid) released June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford. The Texas Health and Human Services Commission issued a Request for Information on April 3, 2026, to explore direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager and group purchasing organization channels. State and local health agencies—specifically county health departments and state HHS commissions—are the primary issuing bodies under this code, targeting community health and pharmacy benefit program objectives rather than individual-dose pharmaceutical procurement.

Geographic activity concentrates in the South and Southwest, with recent opportunities in Florida and Texas. The Seminole County IFB specified quarterly deliveries with a two-year initial contract term and one-year renewal option, requiring electronic bid submission through the county's e-Procurement Portal and fixing a deadline of July 26, 2023, at 2:00 pm; vendors must comply with E-Verify, drug-free workplace certification, and carry workers' compensation, commercial general liability, and professional liability insurance. The Texas HHS RFI, with response due April 3, 2026, functioned as preliminary market intelligence gathering rather than a formal competitive solicitation, seeking vendor capability information on direct pharmaceutical manufacturer relationships and value-based contracting models. Neither opportunity specified budget ranges or set-aside designations at the time of posting.